CRCM  Vol.4 No.1 , January 2015
Bortezomib-Induced Multiple Chalazia: A Case Report
ABSTRACT
Bortezomib is a novel agent for the treatment of patients with multiple myeloma. Several cutaneous lesions have been associated with its use and chalazia have been reported in a few cases with a delayed appearance ranging from 1 to 6 months. We describe the case of a 59-year-old man with multiple myeloma IgG kappa, ISS2, who developed a chalazion induced by bortezomib. Following the failure of conservative treatment, a biopsy was performed to exclude extramedullary plasmocytoma. Bortezomib was discontinued due to the persistence of lesions and a therapeutic approach combining systemic antibiotics with incision and curettage was adopted. An active inflammatory lesion developed after 1 month, similar to that observed under bortezomib therapy. Symptoms resolved only 5 months later and the patient remained free of any ocular manifestation. Physicians should be aware that chalazia may be resistant to conventional treatment and lead to local complications, such as cellulitis.

Cite this paper
Mohamed, R. , Massa, H. , Schwarz, C. , Grandjean-Hallez, N. and Samii, K. (2015) Bortezomib-Induced Multiple Chalazia: A Case Report. Case Reports in Clinical Medicine, 4, 32-35. doi: 10.4236/crcm.2015.41008.
References
[1]   Wojtowicz, J.C., Butovich, I.A., McMahon, A., Hogan, R.N., Itani, K.M., Mancini, R., Molai, M. and Linsenbardt, E. (2014) Time-Dependent Degenerative Transformations in the Lipidome of Chalazia. Experimental Eye Research, 127, 261-269. http://dx.doi.org/10.1016/j.exer.2014.08.008

[2]   Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., Alegre, A., de Arriba, F., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. and San Miguel, J.F. (2008) Bortezomib plus Melphalan and Prednisone in Elderly Untreated Patients with Multiple Myeloma: Updated Time-to-Events Results and Prognostic Factors for Time to Progression. Haematologica, 93, 560-565.
http://dx.doi.org/10.3324/haematol.12106

[3]   Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Diaz-Mediavilla, J., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., de Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., van de Velde, H. and San Miguel, J.F. (2006) Bortezomib plus Melphalan and Prednisone in Elderly Untreated Patients with Multiple Myeloma: Results of a Multicenter Phase 1/2 Study. Blood, 108, 2165-2172. http://dx.doi.org/10.1182/blood-2006-04-019778

[4]   Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. and Anderson, K.C. (2003) A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 348, 2609-2617.
http://dx.doi.org/10.1056/NEJMoa030288

[5]   Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C. and Amato, A.A. (2006) Frequency, Characteristics, and Reversibility of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib. Journal of Clinical Oncology, 24, 3113-3120.
http://dx.doi.org/10.1200/JCO.2005.04.7779

[6]   Agterof, M.J. and Biesma, D.H. (2005) Images in Clinical Medicine. Bortezomib-Induced Skin Lesions. New England Journal of Medicine, 352, 2534. http://dx.doi.org/10.1056/NEJMicm041166

[7]   Pour, L., Hajek, R., Zdenek, A., Krejci, M., Krivanova, A. and Vorlicek, J. (2005) Skin Lesions Induced by Bortezomib. Haematologica, 90, ECR44.

[8]   Min, C.K., Lee, S., Kim, Y.J., Eom, K.S., Lee, J.W., Min, W.S., Kim, C.C., Cho, C.S. and Park, G. (2006) Cutaneous Leucoclastic Vasculitis (LV) Following Bortezomib Therapy in a Myeloma Patient; Association with Pro-Inflammatory Cytokines. European Journal of Haematology, 76, 265-268.
http://dx.doi.org/10.1111/j.0902-4441.2005.t01-1-EJH2437.x

[9]   Truchuelo, M., Bagazgoitia, L., Alcantara, J., Velasco, D. and Carrillo, R. (2012) Sweet-Like Lesions Induced by Bortezomib: A Review of the Literature and a Report of 2 Cases. Actas Dermo-Sifiliograficas, 103, 829-831.
http://dx.doi.org/10.1016/j.ad.2012.03.002

[10]   Wu, K.L., Heule, F., Lam, K. and Sonneveld, P. (2006) Pleomorphic Presentation of Cutaneous Lesions Associated with the Proteasome Inhibitor Bortezomib in Patients with Multiple Myeloma. Journal of the American Academy of Dermatology, 55, 897-900. http://dx.doi.org/10.1016/j.jaad.2006.06.030

[11]   Patrizi, A., Venturi, M., Dika, E., Maibach, H., Tacchetti, P. and Brandi, G. (2014) Cutaneous Adverse Reactions Linked to Targeted Anticancer Therapies Bortezomib and Lenalidomide for Multiple Myeloma: New Drugs, Old Side Effects. Cutaneous and Ocular Toxicology, 33, 1-6.
http://dx.doi.org/10.3109/15569527.2013.787086

[12]   Grob, S.R., Jakobiec, F.A., Rashid, A. and Yoon, M.K. (2014) Chalazia Associated with Bortezomib Therapy for Multiple Myeloma. Ophthalmology, 121, 1845-1847. http://dx.doi.org/10.1016/j.ophtha.2014.04.021

[13]   Zhang, K., Wang, S., Malhotra, J., Hassler, J.R., Back, S.H., Wang, G., Chang, L., Xu, W., Miao, H., Leonardi, R., Chen, Y.E., Jackowski, S. and Kaufman, R.J. (2011) The Unfolded Protein Response Transducer IRE1 Alpha Prevents ER Stress-Induced Hepatic Steatosis. EMBO Journal, 30, 1357-1375. http://dx.doi.org/10.1038/emboj.2011.52

 
 
Top